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Background: Selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and
benzodiazepine anxiolytics are used in the US to treat generalized anxiety disorder (GAD). While benzodiazepines
typically provide rapid symptomatic relief, long-term use is not recommended due to risks of dependency,
sedation, falls, and accidents.
Methods: Using a US health insurance database, we identified all persons with GAD (ICD-9-CM diagnosis code
300.02) who began a long-term course of treatment (≥90 days) with a benzodiazepine anxiolytic between 1/1/2003
and 12/31/2007, We compared healthcare utilization and costs over the six-month periods preceding and following
the date of treatment initiation (“pretreatment” and “post-treatment”, respectively), and focused attention on
accident-related encounters (e.g., for treatment of fractures) and care received for other reasons possibly related
benzodiazepine use (e.g., sedation, dizziness).
Results: A total of 866 patients met all study entry criteria; 25% of patients began treatment on an add-on basis
(i.e., adjunctive to escitalopram, paroxetine, sertraline, or venlafaxine), while 75% of patients did not receive
concomitant therapy. Mean total healthcare costs increased by $2334 between the pretreatment and
post-treatment periods (from $4637 [SD=$9840] to $6971 [$17,002]; p<0.01); costs of accident-related
encounters and other care that was possibly related to use of benzodiazepines increased by an average of $1099
($1757 [$7656] vs $2856 [$14,836]; p=0.03).
Conclusions: Healthcare costs increase in patients with GAD beginning long-term (≥90 days) treatment with a
benzodiazepine anxiolytic; a substantial proportion of this increase is attributable to care associated with accidents
and other known sequelae of long-term benzodiazepine use.
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Generalized anxiety disorder (GAD) is a chronic condi-
tion characterized by persistent worry or anxiety [1];
GAD is often difficult to diagnose because of the wide
variety of clinical presentations and the common occur-
rence of comorbid somatic diseases and/or mental disor-
ders. GAD typically follows a relapsing/remitting pattern;* Correspondence: aberger@pai2.com
1Policy Analysis Inc. (PAI), Brookline, MA, USA
Full list of author information is available at the end of the article
© 2012 Berger et al.; licensee BoiMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orapproximately one-third of patients who achieve remis-
sion experience a full relapse within three years [2].
Lifetime prevalence of GAD has been estimated to be
about 4-6% [3]; one-year prevalence has been reported to
be about 2% [4,5]. GAD is two to three times more com-
mon in women than men [4]. GAD is the most common
anxiety disorder among patients presenting to primary
care physicians [6,7], and it is overrepresented in primary
care settings, with point prevalence rates at least 2–3
times higher than those reported in the community [7,8].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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treatment for many years, selective serotonin reuptake
inhibitors (SSRIs) and serotonin-norepinephrine re-
uptake inhibitors (SNRIs) currently are more frequently
used as first-line treatment for this condition, as these
agents are also effective against depression, which is
common among patients with GAD [9]. However, even
if benzodiazepines are not typically used on a first-line
basis, they are often prescribed adjunctively as they typ-
ically provide rapid symptomatic relief and are relatively
well tolerated. Current guidelines suggest the use of ben-
zodiazepines as short-term concomitant therapy with
recommended first-line antidepressants to speed onset
of efficacy, suppression of increased anxiety associated
with initiation of serotonergic therapy, and/or short-
term relief for crises; long-term use of benzodiazepines
is recommended for patients deemed refractory to other
available therapies [10,11]. There is general agreement
today that benzodiazepines should not be used for more
than a few weeks due to risks of dependency and
sedation, increased risk of falls, industrial and motor
vehicle accidents, and neonatal and infant mortality
when used in late pregnancy or during breast feeding
[12-17]. A substantial proportion of patients receiving
benzodiazepines also develop rebound anxiety, an in-
tensification of previous symptoms, or withdrawal when
treatment is discontinued [18-20]. These concerns are
heightened in older patients, as risk of adverse events
generally increases with age [12-14, 21-23].
In a study using US health insurance data that com-
pared patients with various diagnoses who were pre-
scribed benzodiazepines (n=4454) with those who
received other (i.e., non-benzodiazepine) anxiolytics
(n=13,662), Oster and colleagues reported that patients
in the former group had a 15% higher risk of accident-
related medical events; risk was 30% higher among those
who had filled three or more prescriptions for benzodia-
zepines than among those who had filled only one [24].
The association between use of benzodiazepines and
increased risk of accident/injury (including but not lim-
ited to motor-vehicle accidents, falls, and fractures) has
been confirmed in several subsequent studies [25-32];
benzodiazepines also have been associated with impair-
ment of cognitive and physical function, dizziness, and
sleep impairment [33-38]. Current treatment guidelines
for GAD recommend first-line treatment with antide-
pressants—specifically, escitalopram, paroxetine, or ser-
traline (all selective serotonin re-uptake inhibitors
[SSRI]), or venlafaxine (a serotonin-norepinephrine re-
uptake inhibitor [SNRI])—or pregabalin on the basis of
their efficacy, safety, and tolerability [10,11,39].
While prior research has established the association
between use of benzodiazepines and increased risk of
various adverse events, most of such work has focusedattention on older adults. Moreover, relatively little is
known about the extent to which these risks are experi-
enced among patients with GAD—a condition for which
benzodiazepines often are prescribed. To build upon
prior research, in this study we used data from a large
US healthcare claims database to examine changes in
healthcare utilization and costs in patients with GAD
beginning a long-term (≥90 days) course of treatment
with a benzodiazepine anxiolytic.
Methods
Data source
Data were obtained from the PharMetrics Patient-
Centric Database, which is comprised of facility, profes-
sional-service, and retail (i.e., outpatient) pharmacy
claims from over 85 US health plans. The plans provide
healthcare coverage to approximately 14 million persons
annually throughout the US (Midwest, 35%; Northeast,
21%; South, 31%; West, 13%). All patient identifiers in
the database have been fully encrypted, and the database
is fully compliant with the Health Insurance Portability
and Accountability Act of 1996 (HIPAA). Since there
was no contact with either patients or their providers, all
patient-identifying information was de-identified, and all
analyses were retrospective in nature, Institutional Re-
view Board (IRB) approval was not required.
Information available for each facility and
professional-service claim includes date and place of ser-
vice, diagnoses (in ICD-9-CM format), procedures (in
ICD-9-CM [selected plans only], Current Procedural
Terminology, 4th Edition [CPT-4], and HCPCS formats),
and provider specialty. Data available for each retail
pharmacy claim include the drug dispensed (in NDC
format), the dispensing date, and the quantity dispensed
and number of days of therapy supplied (selected plans
only). All claims include both charged and paid
amounts, the latter including patient deductibles, copay-
ments, and/or coinsurance.
Selected demographic and eligibility information is
also available, including age, gender, geographic region,
coverage type, and the dates of insurance coverage. All
patient-level data can be arrayed in chronologic order
to provide a detailed, longitudinal profile of all medical
and pharmacy services used by each plan member. The
database for this study encompassed the period from
January 1, 2003 through December 31, 2007 (“study
period”).
Study sample
We identified all patients with two or more paid claims
for outpatient encounters on different days with a diag-
nosis of GAD (ICD-9-CM diagnosis code 300.02) be-
tween 1/1/2003 and 12/31/2007. Among these persons,
we limited attention to those who were beginning a
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months) with a benzodiazepine anxiolytic (i.e., alprazo-
lam, chlordiazepoxide, clonazepam, clorazepate, diaze-
pam, lorazepam, oxazepam) (“study agents”). Date of
treatment initiation was designated the “index date”. We
excluded from the study sample all patients: (1) with any
evidence of receipt of benzodiazepines prior to their
index date; (2) with one or more days of ineligibility for
medical and pharmacy benefits over the 6-month peri-
ods immediately preceding and following their index
dates (“pretreatment” and “post-treatment”, respectively);
(3) who were Medicaid beneficiaries; or (4) aged ≥65
years as of their index date and enrolled in a Medicare
supplemental or fee-for-service plan (their claims histor-
ies may be incomplete). We then stratified patients
according to whether they received a benzodiazepine
anxiolytic alone (“monotherapy cohort”) or adjunctive to
escitalopram, paroxetine, sertraline, or venlafaxine
(“add-on” cohort), as described below.
To maximize the likelihood that patients in the mono-
therapy cohort were initiating treatment for GAD, we
required that they have at least one healthcare encounter
with a diagnosis code of GAD in the 90-day period imme-
diately preceding (and including) their index date, and no
evidence of receipt of any other GAD-related medication (i.
e., escitalopram, paroxetine, sertraline, venlafaxine, imipra-
mine, buspirone, hydroxyzine, trifluoperazine) [9,40] or any
other agent from any corresponding class of medication (e.
g., selective serotonin reuptake inhibitors [SSRIs]) during
the 6-month pretreatment period.
Patients in the add-on cohort were required to have at
least one claim with a diagnosis code of GAD as well as
evidence of extended (≥90 days) receipt of escitalopram,
paroxetine, sertraline, or venlafaxine (all recommended as
first-line treatment for GAD in recent clinical guidelines
[9,41]) during the 6-month period preceding initiation of
benzodiazepine therapy (a longer time period was used for
the add-on cohort than the monotherapy cohort, as GAD
diagnoses may not be rendered as frequently in patients
receiving long-term therapy). They also had to have evi-
dence of receipt of these agents in the 90-day period fol-
lowing their index date.
Patients not meeting criteria for either the monother-
apy or add-on cohorts were dropped from the study
sample. For all remaining patients, we compiled all phar-
macy, professional service, and facility claims during
both the pre-index and post-index periods.Measures and analyses
The demographic and clinical characteristics of study sub-
jects, including prevalence of selected comorbidities (Ap-
pendix), were characterized on the basis of information
during the 6-month pre-index period.All healthcare encounters with ICD-9-CM diagnosis
codes in the ranges 800.XX-959.XX, 990.XX-995.XX,
E800.X-E849.X, E880.X-E889.X, E916.X-E929.X, and
V155.5 were considered to be “accident-related,” following
methods first employed by Oster et al. [24]. Healthcare
encounters for other potential adverse consequences of
long-term benzodiazepine therapy were identified based
on visits/admissions for known sequelae of benzodiazep-
ine use [33–38], as follows: (1) drug dependence/addic-
tion/poisoning (ICD-9-CM diagnosis codes 304.1X,
304.9X, 305.4, 969.4, V58.69, E853.2, E980.3); (2) with-
drawal syndrome (292.0X); (3) drowsiness (780.09); (4)
ataxia (781.2, 781.3); (5) dysarthria (784.5); (6) diplopia
(368.2); (7) vertigo/dizziness (780.4); (8) mental confusion/
disorientation (292.8X, 292.9X, 293.0, 780.1, 780.2); (9)
cognitive impairment (780.02, 780.09, 780.93, 780.97); and
(10) other adverse effects recorded that related to benzo-
diazepine therapy (E939.4, E950.3). These encounters were
denoted, collectively, as “other possibly related” care.
We also examined patterns of healthcare utilization
during the pretreatment and post-treatment periods in
terms of the numbers of physician office visits, other
outpatient office visits, emergency department (ED) vis-
its, and hospitalizations. Use of these services was exam-
ined in terms of the numbers of patients receiving each
type of service, as well as counts of the numbers of
ervices used (e.g., office visits, hospitalizations). All
healthcare encounters and corresponding costs were
designated as “accident-related”, “other possibly related”,
or “other”, depending on the ICD-9-CM diagnosis code
(s) noted on each claim. Total healthcare costs were tal-
lied in terms of: (1) prescription pharmacotherapy; (2)
physician office visits; (3) other outpatient visits; (4) ED
visits; (5) inpatient care; and (6) all other care. Reim-
bursed amounts (including any patient liability, such as
co-pays and co-insurance) were used in all analyses of
healthcare costs. Healthcare utilization and costs were
assessed over the 6-month pretreatment and post-
treatment periods, respectively.
Since patients served as their own controls in the ana-
lyses, the statistical significance of differences in health-
care costs between the pretreatment and post-treatment
periods was assessed using Wilcoxon signed-rank tests;
McNemar and Bowker’s tests were used to assess the
statistical significance of differences in categorical vari-
ables. All tests of statistical significance were two-tailed
with an alpha level of 0.05. All analyses were first per-
formed by cohort and, within each cohort, on an overall
basis as well as for patients aged <50 years versus ≥50
years, respectively. Finally, analyses were performed for
the two cohorts combined, on an overall basis as well as
by age stratum (<50 years vs ≥50 years). All analyses
were conducted using SASW Proprietary Software, Re-
lease 9.1 (SAS Institute Inc., Cary, NC).
Table 1 Demographic and clinical characteristics of GAD
patients designated as long-term benzodiazepine users,
by age





Mean (SD) age, years 35.8 (9.7) 57.6 (7.1) 43.3 (13.6)
Women 293 (51.6) 169 (56.7) 462 (53.3)
Comorbidities
Mental disorders
Other anxiety disorders 105 (18.5) 43 (14.4) 148 (17.1)
Depressive disorders 259 (45.6) 133 (44.6) 392 (45.3)
Bipolar disorder 9 (1.6) 5 (1.7) 14 (1.6)
Tension headache 6 (1.1) 2 (0.7) 8 (0.9)
Personality disorders 7 (1.2) 4 (1.3) 11 (1.3)
Alcohol abuse/alcoholism 3 (0.5) 2 (0.7) 5 (0.6)
Drug abuse 15 (2.6) 2 (0.7) 17 (2.0)
Suicide attempts 13 (2.3) 5 (1.7) 18 (2.1)
All other
Sleep disorders 65 (11.4) 47 (15.8) 112 (12.9)
Neoplasms 8 (1.4) 15 (5.0) 23 (2.7)
Diabetes 12 (2.1) 36 (12.1) 48 (5.5)
Migraine 17 (3.0) 10 (3.4) 27 (3.1)
Ischemic heart disease 2 (0.4) 14 (4.7) 16 (1.8)
Cerebrovascular disease 6 (1.1) 8 (2.7) 14 (1.6)
Asthma 23 (4.0) 19 (6.4) 42 (4.8)
Painful neuropathic disorders 54 (9.5) 45 (15.1) 99 (11.4)
Symptoms, signs, and ill-defined conditions
Fatigue 71 (12.5) 45 (15.1) 116 (13.4)
Headache 50 (8.8) 20 (6.7) 70 (8.1)
Chest pain 55 (9.7) 31 (10.4) 86 (9.9)
Abdominal pain 65 (11.4) 31 (10.4) 96 (11.1)
Anxiety-related symptoms 72 (12.7) 48 (16.1) 120 (13.9)
Any symptoms, signs, and
ill-defined conditions
211 (37.1) 119 (39.9) 330 (38.1)
Region
Northeast 164 (28.9) 84 (28.2) 248 (28.6)
South 140 (24.6) 54 (18.1) 194 (22.4)
West 92 (16.2) 55 (18.5) 147 (17.0)
Midwest 172 (30.3) 105 (35.2) 277 (32.0)
Payer type
HMO 138 (24.3) 63 (21.1) 201 (23.2)
PPO 300 (52.8) 152 (51.0) 452 (52.2)
Indemnity 25 (4.4) 22 (7.4) 47 (5.4)
Other 33 (5.8) 19 (6.4) 52 (6.0)
*Unless otherwise noted, all values are numbers of patients (%).
GAD: Generalized anxiety disorder; HMO: Health maintenance organization;
PPO: Preferred provider organization.
Berger et al. BMC Psychiatry 2012, 12:177 Page 4 of 10
http://www.biomedcentral.com/1471-244X/12/177Results
We identified a total of 866 patients with GAD who
began a long-term course of treatment (≥90 days) with
a benzodiazepine anxiolytic; 25% of patients began
treatment on an add-on basis (i.e., adjunctive to escita-
lopram, paroxetine, sertraline, or venlafaxine), while
75% of patients did not receive concomitant therapy.
Mean (SD) age was 43.3 (13.6) years, and 53.3% were
women (Table 1). Forty-five percent of study subjects
had evidence of comorbid depression. Mean age was
similar in the monotherapy and add-on cohorts (about
43 years); the latter were more likely to be women,
however (65% vs 50% of those in the monotherapy co-
hort), and to have comorbid depression (61% vs 40%)
(data available upon request).
Changes in the number of persons with accident-
related and other possibly related encounters between
the pretreatment and post-treatment periods were minor
and not statistically significant, irrespective of age
(Table 2). Mean numbers of outpatient visits for
accident-related and other possibly related care
increased significantly between the two periods, however
(from 6.1 [17.3] to 8.0 [20.2]; p<0.01).
Mean (SD) total healthcare costs increased by an aver-
age of $2334 between the pretreatment and post-
treatment periods ($4637 [$9840] vs $6971 [$17,002];
p<0.01); the difference in median costs was $1414 ($1805
during pre-treatment period vs $3219 for during post-
treatment period) (Table 3). Total healthcare costs
increased by $2980 among patients aged ≥50 years
($6211 [$13,308] vs 9191 [22,540]; p=0.01), and by $1994
among patients aged <50 years ($3812 [$7278] vs $5806
[$13,073]; p<0.01); corresponding median increases were
$1623 (median [IQR] = $2381 [$816, $6017] vs $4004
[$1886, $8409]) and $1285 ($1540 [$495, $3723] vs
$2825 [$1304, $5767]). Mean costs for accident-related
and other possibly related care increased by $1099 be-
tween the two periods ($1757 [$7656] vs $2856
[$15,742]; p=0.03). Patients aged ≥50 years experienced
nominally greater increases in these costs than those
who were younger ($1559 and $858, respectively).
Findings with respect to accident-related and other
possibly related care were similar for patients in the
monotherapy and add-on cohorts. Among patients in
the monotherapy cohort, mean total healthcare costs
increased from $3753 ($9675) during the pretreatment
period to $6073 ($15,714) during the post-treatment
period (p<0.01) (median cost increased by $1404). For
patients in the add-on cohort, mean total healthcare
costs increased from $7396 ($9858) during the pretreat-
ment period to $9746 ($20,241) during the post-
treatment period (p=0.06) (median cost increased by
$1524). Mean costs of accident-related and other pos-
sibly related care increased by $1116 among patients in
Table 2 Use of healthcare services during pre- and post-index periods among all GAD patients newly started on
benzodiazepines, by age*
Healthcare Service Patient Age All Patients (N=866)
<50 Years (N=568) ≥50 Years (N=298)
Pre-Index Post-Index P-Value Pre-Index Post-Index P-Value Pre-Index Post-Index P-Value
Outpatient care
Outpatient office visits
Number (%) with ≥1 visits
Accident-related 102 (18.0) 106 (18.7) 0.72 51 (17.1) 53 (17.8) 0.80 153 (17.7) 159 (18.4) 0.66
Other possibly related 60 (10.6) 69 (12.1) 0.33 37 (12.4) 32 (10.7) 0.47 97 (11.2) 101 (11.7) 0.73
All of above 142 (25.0) 152 (26.8) 0.45 79 (26.5) 73 (24.5) 0.51 221 (25.5) 225 (26.0) 0.80
All other 379 (66.7) 410 (72.2) 0.03 209 (70.1) 223 (74.8) 0.14 588 (67.9) 633 (73.1) <0.01
All 521 (91.7) 562 (98.9) <0.01 288 (96.6) 296 (99.3) 0.02 809 (93.4) 858 (99.1) <0.01
Mean (SD) number of visits
Accident-related 4.2 (14.3) 5.3 (15.0) 0.15 5.9 (19.9) 6.4 (19.2) 0.69 4.8 (16.4) 5.7 (16.5) 0.18
Other possibly related 2.5 (11.2) 3.6 (12.8) 0.06 3.0 (12.1) 5.7 (23.9) 0.05 2.7 (11.5) 4.3 (17.4) <0.01
All of above 5.5 (15.3) 7.2 (16.6) 0.02 7.4 (20.5) 9.6 (25.7) 0.11 6.1 (17.3) 8.0 (20.2) <0.01
All other 8.0 (13.7) 11.6 (15.9) <0.01 12.8 (24.3) 17.7 (24.7) <0.01 9.6 (18.2) 13.7 (19.6) <0.01
All 13.4 (18.2) 18.8 (19.1) <0.01 20.2 (28.7) 27.3 (30.5) <0.01 15.8 (22.6) 21.7 (23.9) <0.01
ED visits
Number (%) with ≥1 visits
Accident-related 44 (7.7) 48 (8.5) 0.60 15 (5.0) 15 (5.0) >0.99 59 (6.8) 63 (7.3) 0.67
Other possibly related 36 (6.3) 23 (4.0) 0.06 9 (3.0) 14 (4.7) 0.28 45 (5.2) 37 (4.3) 0.33
All of above 67 (11.8) 61 (10.7) 0.51 21 (7.0) 24 (8.1) 0.62 88 (10.2) 85 (9.8) 0.79
All other 51 (9.0) 58 (10.2) 0.44 18 (6.0) 24 (8.1) 0.29 69 (8.0) 82 (9.5) 0.23
All 118 (20.8) 119 (21.0) 0.93 39 (13.1) 48 (16.1) 0.26 157 (18.1) 167 (19.3) 0.48
Mean (SD) number of visits
Accident-related 0.7 (3.7) 1.0 (6.1) 0.27 0.6 (3.4) 1.3 (15.5) 0.47 0.7 (3.6) 1.1 (10.3) 0.25
Other possibly related 0.8 (4.8) 0.7 (5.5) 0.47 1.1 (15.1) 1.4 (15.6) 0.24 0.9 (9.6) 0.9 (10.2) 0.92
All of above 1.2 (5.2) 1.3 (6.5) 0.88 1.6 (15.4) 1.6 (15.7) 0.81 1.4 (9.9) 1.4 (10.6) 0.98
All other 0.8 (4.0) 1.0 (4.7) 0.43 0.6 (3.1) 0.8 (4.0) 0.51 0.7 (3.7) 0.9 (4.5) 0.30
All 2.1 (6.4) 2.3 (7.9) 0.49 2.2 (15.6) 2.3 (16.1) 0.72 2.1 (10.5) 2.3 (11.4) 0.44
Hospitalizations
Number (%) with ≥1 hospitalizations
Accident-related 11 (1.9) 13 (2.3) 0.67 8 (2.7) 7 (2.3) 0.76 19 (2.2) 20 (2.3) 0.86
Other possibly related 12 (2.1) 13 (2.3) 0.83 8 (2.7) 10 (3.4) 0.56 20 (2.3) 23 (2.7) 0.60
All of above 18 (3.2) 22 (3.9) 0.50 12 (4.0) 11 (3.7) 0.78 30 (3.5) 33 (3.8) 0.67
All other 23 (4.0) 17 (3.0) 0.29 14 (4.7) 11 (3.7) 0.44 37 (4.3) 28 (3.2) 0.19
All 41 (7.2) 39 (6.9) 0.80 26 (8.7) 22 (7.4) 0.41 67 (7.7) 61 (7.0) 0.51
Mean (SD) number of hospitalizations
Accident-related 0.7 (6.1) 1.2 (11.2) 0.38 1.1 (8.6) 1.3 (10.1) 0.75 0.9 (7.0) 1.2 (10.8) 0.36
Other possibly related 0.9 (7.3) 1.3 (12.1) 0.52 1.5 (10.9) 1.7 (11.0) 0.74 1.1 (8.7) 1.4 (11.7) 0.48
All of above 1.2 (8.1) 1.7 (13.0) 0.40 1.7 (11.1) 1.8 (11.0) 0.98 1.4 (9.3) 1.7 (12.4) 0.47
All other 0.9 (5.9) 0.5 (4.1) 0.13 1.7 (9.0) 0.8 (5.9) 0.11 1.2 (7.1) 0.6 (4.8) 0.03
All 2.2 (9.9) 2.2 (13.6) 0.94 3.5 (14.1) 2.6 (12.4) 0.30 2.6 (11.6) 2.3 (13.2) 0.56
GAD: Generalized anxiety disorder; SD: Standard deviation; ED: Emergency department.
Berger et al. BMC Psychiatry 2012, 12:177 Page 5 of 10
http://www.biomedcentral.com/1471-244X/12/177
Table 3 Total healthcare costs during pre- and post-index periods among al l GAD patients newly started on benzodiazepines, by age*
Patient Age All Patients (N=866)
<50 Years (N=568) ≥50 Years (N=298)
Pre-Index Post-Index P-Value Pre-Index Post-Index P-Value Pre-Index Post-Index P-Value
Pharmacotherapy
Mean (SD) 583 (1,660) 1,295 (1,789) <0.01 829 (1,446) 1,873 (2,318) <0.01 668 (1,593) 1,494 (2,005) <0.01




Mean (SD) 437 (2,368) 518 (1,757) 0.46 591 (2,203) 749 (2,687) 0.27 490 (2,312) 598 (2,125) 0.22
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
Other possibly related
Mean (SD) 287 (2,101) 418 (1,695) 0.19 297 (1,627) 624 (2,901) 0.04 290 (1,950) 489 (2,187) 0.02
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
All of above
Mean (SD) 552 (2,416) 766 (2,095) 0.07 701 (2,221) 1,099 (3,425) 0.03 603 (2,351) 881 (2,633) <0.01
Median (IQR) 0 (0, 42) 0 (0, 422) — 0 (0, 78) 0 (0, 0) — 0 (0, 78) 0 (0, 315) —
All other
Mean (SD) 802 (2,300) 1,228 (2,913) <0.01 1,331 (2,939) 1,840 (3,502) 0.03 984 (2,549) 1,439 (3,140) <0.01
Median (IQR) 211 (0, 822) 432 (0, 1,300) — 395 (0, 1,368) 678 (0, 2,061) — 247 (0, 985) 483 (0, 1,565) —
All
Mean (SD) 1,354 (3,201) 1,995 (3,315) <0.01 2,032 (3,421) 2,938 (4,465) <0.01 1,587 (3,292) 2,319 (3,775) <0.01
Median (IQR) 533 (187, 1,455) 993 (430, 2,239) — 845 (363, 2,174) 1,520 (548, 3,274) — 641 (221, 1,623) 1,171 (463, 2,563) —
ED visits
Accident-related
Mean (SD) 99 (538) 143 (934) 0.16 59 (384) 161 (2,004) 0.39 85 (490) 149 (1,397) 0.16
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
Other possibly related
Mean (SD) 116 (708) 99 (838) 0.57 96 (1,328) 178 (2,021) 0.08 109 (966) 126 (1,365) 0.50
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
All of above
Mean (SD) 173 (768) 180 (976) 0.84 150 (1,377) 207 (2,036) 0.23 165 (1,019) 189 (1,431) 0.40

















Table 3 Total healthcare costs during pre- and post-index periods among al l GAD patients newly started on benzodiazepines, by age* (Continued)
All other
Mean (SD) 105 (547) 122 (554) 0.57 75 (440) 111 (677) 0.42 94 (513) 118 (599) 0.35
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
All
Mean (SD) 278 (924) 302 (1,103) 0.60 225 (1,438) 317 (2,135) 0.15 259 (1,127) 307 (1,537) 0.20
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
Hospitalizations
Accident-related
Mean (SD) 357 (3,235) 873 (10,042) 0.24 871 (7,386) 1,660 (17,048) 0.42 534 (5,065) 1,144 (12,885) 0.17
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
Other possibly related
Mean (SD) 341 (2,898) 778 (9,468) 0.28 1,031 (8,303) 2,025 (17,635) 0.33 578 (5,412) 1,207 (12,880) 0.16
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
All of above
Mean (SD) 508 (3,650) 1,131 (10,472) 0.17 1,202 (8,516) 2,090 (17,663) 0.39 747 (5,809) 1,461 (13,387) 0.13
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
All other
Mean (SD) 444 (2,655) 252 (2,255) 0.18 865 (5,774) 396 (2,906) 0.20 589 (4,014) 301 (2,498) 0.07
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
All
Mean (SD) 953 (4,463) 1,382 (10,685) 0.35 2,067 (10,187) 2,485 (17,854) 0.70 1,336 (6,998) 1,762 (13,585) 0.38
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
All other care
Accident-related
Mean (SD) 80 (542) 78 (712) 0.95 124 (596) 247 (1,654) 0.18 95 (561) 136 (1,131) 0.30
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
Other possibly related
Mean (SD) 63 (353) 55 (326) 0.65 100 (606) 267 (2,364) 0.23 76 (456) 128 (1,414) 0.29
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
All of above
Mean (SD) 118 (599) 118 (759) >0.99 177 (754) 423 (2,772) 0.13 138 (657) 223 (1,743) 0.16

















Table 3 Total healthcare costs during pre- and post-index periods among al l GAD patients newly started on benzodiazepines, by age* (Continued)
All other
Mean (SD) 154 (540) 253 (1,405) 0.07 381 (1,535) 544 (2,845) 0.32 232 (1,006) 353 (2,023) 0.07
Median (IQR) 0 (0, 61) 0 (0, 63) — 4 (0, 175) 9 (0, 224) — 0 (0, 98) 0 (0, 106) —
All
Mean (SD) 272 (784) 371 (1,578) 0.13 559 (1,670) 967 (3,913) 0.06 370 (1,174) 576 (2,640) 0.02
Median (IQR) 16 (0, 191) 22 (0, 164) — 84 (0, 374) 91 (0, 424) — 37 (0, 237) 35 (0, 247) —
Total
Accident-related
Mean (SD) 1,025 (4,833) 1,662 (11,324) 0.20 1,787 (9,131) 2,947 (19,831) 0.26 1,287 (6,638) 2,104 (14,814) 0.09
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
Other possibly related
Mean (SD) 835 (4,628) 1,381 (10,518) 0.21 1,594 (10,275) 3,174 (21,009) 0.17 1,096 (7,101) 1,998 (14,993) 0.07
Median (IQR) 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) — 0 (0, 0) 0 (0, 0) —
All of above
Mean (SD) 1,414 (5,387) 2,272 (11,880) 0.09 2,411 (10,709) 3,970 (21,224) 0.16 1,757 (7,656) 2,856 (15,742) 0.03
Median (IQR) 0 (0, 148) 0 (0, 539) — 0 (0, 295) 0 (0, 0) — 0 (0, 217) 0 (0, 397) —
All other
Mean (SD) 2,247 (5,378) 3,122 (6,209) <0.01 3,505 (8,635) 4,664 (7,608) 0.04 2,680 (6,702) 3,653 (6,759) <0.01
Median (IQR) 533 (0, 2,122) 1,343 (0, 3,521) — 943 (0, 3,575) 2,263 (183, 5,746) — 635 (0, 2,519) 1,528 (0, 4,236) —
All
Mean (SD) 3,812 (7,278) 5,806 (13,073) <0.01 6,211 (13,308) 9,191 (22,540) 0.01 4,637 (9,840) 6,971 (17,002) <0.01
Median (IQR) 1,540 (495, 3,723) 2,825 (1,304, 5,767) — 2,381 (816, 6,017) 4,004 (1,886, 8,409) — 1,805 (584, 4,590) 3,219 (1,460, 6,654) —
*All values are healthcare costs ($).
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[$14,836]; p=0.04), and by $1050 for those in the add-on
cohort (from $1675 [$4574] to $2726 [$18,283]; p=0.37).
Discussion
In our study, patients with GAD who began a long-term
(≥90 days) course of therapy with a benzodiazepine anxio-
lytic had significantly higher healthcare costs during the
6-month period following initiation of therapy than in the
6 months preceding it. This finding is not unexpected,
since initiation of benzodiazepine therapy is undoubtedly
a marker for exacerbation of GAD and thus may foretell
higher costs associated with the diagnosis and treatment
of various associated psychic and somatic conditions. In
two previous studies, we found that total healthcare costs
were significantly higher following initiation of pharmaco-
therapy for GAD (either on a first-line basis or as add-on
treatment) [42,43]. It is notable that in our current study
almost one-half the increase in healthcare costs (47%) was
attributable to medical encounters for reasons related to
well-known side effects of long-term use of benzodiazep-
ine anxiolytics (e.g., falls and other accidents, somnolence,
vertigo, dizziness, and cognitive impairment).
Our study has a number of limitations. First, as with all
studies based on healthcare claims databases, there may
be errors of omission and commission in coding. Accord-
ingly, some patients with GAD may not have been
included in our study sample due to absence of appropri-
ate and/or misdiagnoses on healthcare claims, while
others who received a diagnosis of GAD incorrectly and
therefore should have been excluded were not. As patient
medical records were not available to us, the degree to
which patients were actually misclassified is unknown.
Also, the database does not contain important clinical in-
formation on disease severity. Such information, if
present, might have permitted further analysis of the over-
all cost increase. Another potential limitation was the
omission of fluoxetine from the group of SSRIs qualifying
patients for the add-on group. We excluded fluoxetine be-
cause it is not indicated for the treatment of GAD, and be-
cause it has not been studied extensively in this indication.
Nonetheless, there is evidence that it may be widely pre-
scribed for this disorder [44-46]. In one recent study of
305 patients with GAD and 232 with social phobia, it was
reported to be the most commonly prescribed SSRI [47].
Unless, however, patients receiving benzodiazepines as an
adjunct to fluoxetine differ critically from those adding on
to the other SSRIs, this omission would not have biased
our study. Our findings are based on retrospective ana-
lyses of a US health insurance database; the degree to
which results reported herein are generalizable to the ex-
perience of patients with GAD in other countries, where
the medications indicated for the treatment GAD may dif-
fer from that in the US, is unknown. Finally, numerous p-values were calculated in our study, and we made no
attempt to adjust for “multiplicity”. Thus, borderline
p-values (e.g., 0.03, 0.04) should be interpreted cau-
tiously. On the other hand, the costs increases we found
were substantial, while the number of study subjects was
relatively small and the standard deviations of the cost
increases were relatively large. P-values that were border-
line in this study would almost certainly have been
unequivocally significant in a larger study.
Conclusions
In conclusion, healthcare costs increased in patients with
GAD following initiation of a long-term course of ther-
apy with a benzodiazepine anxiolytic and approximately
one-half of this increase was attributable to care asso-
ciated with known sequelae of long-term use of such
therapy. Thus our results appear to support the need for
consideration of alternative treatment options for GAD
that are relatively free of the bothersome side effects and
potential for abuse associated with benzodiazepines.
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